1 |
Park, H.-W, Boduluri, S. R, Moornaw, J. F., Casey, P. J. and Beese, L. S., Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science, 275, 1800-1805 (1997)
DOI
PUBMED
ScienceOn
|
2 |
Cadena, D. L. and Gill, G. N., Receptor tyrosine kinases. FASEB J., 6, 2332-2337 (1992)
DOI
PUBMED
|
3 |
Bos, J. L., Ras Oncogenes in human cancer. Cancer Res., 49, 4682-4689 (1989)
PUBMED
|
4 |
Casey, P. J., Solski, P. A, Der, C. J. and Buss, J. E., p21 Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA, 86, 8323-8327 (1989)
DOI
ScienceOn
|
5 |
Cox, A D. and Der, C. J., Farnesyltransferase inhibitors and cancer treatment: Targetingsimply Ras?. Biochim. Biophy Acta., 1333, F51-F71(1997)
|
6 |
Barbacid, M., Ras gene. Annu. Rev. Biochem., 56, 779-827 (1987)
DOI
PUBMED
ScienceOn
|
7 |
Brown, M. S., Goldstein, J. L., Paris, K. J., Burnier, J. P. and Marsters, J. J., Tetrapeptide inhibitors of protein farnesyItransferase: Amino-terminal substitution in phenylalaninecontaining tetrapeptides restores farnesylation. Proc. Natl. Acad.Sci. USA, 89, 8313-8316 (1992)
DOI
ScienceOn
|
8 |
Casey, P. J., Biochemistry of protein prenylation. J. Lipid Res., 33, 1731-1740 (1992)
PUBMED
|
9 |
Dunten, P, Kammlott, U., Crowther, R., Weber, D., Palermo, R. and Birktoft, J., Protein farnesyltransferase: Structure and implications for substrate binding. Biochemistry, 37, 7907-7912 (1998)
DOI
ScienceOn
|
10 |
Gutierrez, L., Magee, A. I., Marshall, C. J. and Hancock, J. F, Post-translational processing of p21 ras is two-step and involves carboxyl-rnethylation and carboxyterminal proteolysis. EMBO J., 8, 1093-1098 (1989)
PUBMED
|
11 |
Hamilton, A D. and Sebti, S. M., Inhibitors of Ras farnesyltransferase as novel antitumor agents. Drug News Perspect., 8, 138-145 (1995)
|
12 |
Hunt, J. T, Lee, Y. G., Leftheris, K., Seizinger, B., Carboni, J., Mabus, J., Ricca, C., Yan, N. and Manne, V, Potent, cell active, non-thiol tetrapeptide inhibitors offarnesyltransferase. J. Med. Chem., 39, 353-358 (1996)
DOI
ScienceOn
|
13 |
McCormick, F., Ras GTPase activating protein: Signal transmitter and signalterminator. Cell, 56, 5-8 (1989)
DOI
PUBMED
ScienceOn
|
14 |
Lowy, D. R. and Willumsen, B. M., Function and regulation of Ras. Annu. Rev. Biochem.,62, 851-891 (1993)
DOI
ScienceOn
|
15 |
Maignan, S., Guilloteau, J.-P., Fromage, N., Arnoux, B., Becquart, J. and Ducruix, A, Crystal structure of the mammalian Grb2 adaptor. Science, 268, 291-293 (1995)
DOI
PUBMED
|
16 |
Masrers, J. C., Jr., McDowell, R. S., Reynilds, M. E, Oare, D. A., Somers, T. C., Stanley,M. S., Rawson, T. E., Struble, M. E., Burdick, D. J., Chan, K. S., Duarte, C. M., Paris, K. J., Tom, J. Y, Wan, D. T, Xue, Y and Burnier, J. P., Benzodiazepinepeptidomimetic inhibitors of farnesylferase. Bioorg. Med. Chem., 2, 949-957(1994)
DOI
ScienceOn
|
17 |
McCormick, F, How receptors turn Ras on. Nature, 363, 15-16 (1993)
DOI
PUBMED
ScienceOn
|
18 |
Mu, Y, Omer, C. A and Gibbs, R. A, On the stereochemical course of human protein farnesyltransferaes. J. Am. Chem. Soc., 118, 1817-1823(1996)
DOI
ScienceOn
|
19 |
Patel, D. V., Gordon, E. M., Schmidt, R. J., Weller, H. N., Young, M. G., Zahler, R, Barbacid, M., Carboni, J. M., GulloBrown, J. L., Huniham, L., Ricca, C., Robinson, S., Seizinger, B. R, Tuomari, A V and Mann, V, Phosphinyl acid-based bisubstrate analog inhibitors of Ras famesyl protein transferase. J. Med. Chem., 38, 435-442 (1995)
DOI
ScienceOn
|
20 |
Stricklanc, C. L., Windsor, W. T., Syto, R., Wang, L., Bond, R., Wu, Z. Schwartz, J., Le, H. V., Beese, L. S. and Weber, P. C., Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry, 37, 16601-16611(1998)
DOI
ScienceOn
|
21 |
Edelstein, R. L., Weller, V. A. and Distefano, M. D., Stereo chemical analysis of the reaction catalyzed by yeast protein famesyltransferase. J. Org. Chem., 63, 5298-5299 (1998)
DOI
ScienceOn
|
22 |
Weller, V. A and Distefano, M. D., Measurement of the -Secondary kinetic isotope effect for a prenyltransferase by MALDI mass spectrometry. J. Am. Chem. Soc., 120, 7975-7976 (1998)
DOI
ScienceOn
|
23 |
Moodie, S. A. and Wolfman, A., The 3Rs of life: Ras, Raf and Growth regulation. TlG,10, 44-48 (1994)
|
24 |
Hancock, J. F., Magee, A. I., Childs, J. E. and Marshall, C. J., All ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167-1177 (1989)
DOI
ScienceOn
|
25 |
Matthews, R. G. and Goulding, C. W., Enzyme-catalyzed methyl transfers to thiols: Therole of zinc. Curr. Opin. Chem. Biol., 1, 332-339(1997)
DOI
ScienceOn
|
26 |
Reiss, Y, Brown, M. S. and Goldstein, J. L., Divalent cation and prenyl pyrophosphate specificities of the protein famesyl transferase from rat brain, a zinc metalloenzyme. J. Biol. Chem., 267, 6403-6408 (1992)
PUBMED
|
27 |
Pai, E. F., Krengel, U., Gregoty, A. P., Goody, R. S., Kabsch, W. and Wittinghofer, A., Refiend crystal Structure of the triphosphate conformation of H-ras p21 at 1.35 Aresolution: Implications for the mechanism of GTP hydrolysis. EMBO J., 9, 2351-2359 (1990)
PUBMED
|
28 |
Leonard, D. M., Ras famesyltransferase: A new therapeutic target. J. Med. Chem., 40, 2971-2990 (1997)
DOI
PUBMED
ScienceOn
|
29 |
Dolence, J. M. and Poulter,C. D., A mechanism for posttranslationaI modifications of proteins by yeast protein farnesyltransferase. Proc. Natl. Acad. Sci. USA, 92, 5008-5011 (1995)
DOI
ScienceOn
|
30 |
Krengel, U., Schlichting, I., Scherer, A., Schumann, R., French, M., John, J., Kabsch, W, Pai, E. F. and Wittinghofer, A., Three-dimensional structures of H-ras p21mutants: Molecular basis for their inability to function as signal switch molecules. Cell, 62, 539-548 (1990)
DOI
ScienceOn
|
31 |
Casey, P. J. and Seabra, M. C., Protein prenyltransferases. J. Biol. Chem., 271, 5289-5292 (1996)
DOI
PUBMED
|
32 |
Clerc, F.-F., Guitton, J.-D., Fromage, N., Lelievre, Y., Duchesne, M., Tocque, B., JamesBurcouf, E., Commercon, A. and Becquart, J., Constrained analogues of kcvfm with improved inhibitory properties against farnesyltransferase. Bioorg. Med.Chem., 5, 1779-1784 (1995)
DOI
ScienceOn
|
33 |
Fearon, E. R, Human cancer syndromes. Science, 278, 1043-1050(1997)
DOI
PUBMED
ScienceOn
|
34 |
Hinterding, K., Alonso-Diaz, D. and Waldmann, H. Organic synthesis and biological signal transduction. Angew. Chem. Int. Ed. Engl., 37, 688-749 (1998)
DOI
ScienceOn
|
35 |
Kobran, K. S., Culberson, J. C., Desolms, S. J., Giuliani, E. A, Mosser, S. D., Omer, C.A., Pitzenberger, S. M. and Bogusky, M. J., NMR studies of novel inhibitors bound to farnesyl protein transferase. Protein Sci., 4, 681-688 (1995)
DOI
PUBMED
ScienceOn
|
36 |
Barinaga, M., From bench top to bedside. Science, 278, 1036-1039 (1997)
DOI
PUBMED
ScienceOn
|
37 |
Long, S. B. and Casey, P. J., Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry, 37, 9612-9618 (1998)
DOI
ScienceOn
|
38 |
Park, H.-W. and Beese, L. S., Protein farnesyltransferase. Curr. Opin. Struct. Biol., 7,873-880 (1997)
DOI
ScienceOn
|
39 |
Reiss, Y, Goldstein, J. L., Seabra, M. C., Casey, P. J. and Brovn, M. S., Inhibition of purified p21 ras farnesyl protein transfease by Cys-AAX tetrapeptide. Cell, 62, 81-88 (1990)
DOI
ScienceOn
|
40 |
Buss, J. E. and Marsters, J. C., Jr., Farnesyl transferase inhibitors: The successes andsurprises of new class of potential cancer chemotherapeutics. Chemistry & Biology, 2, 787-791 (1995)
DOI
ScienceOn
|
41 |
Willumsen, B. M., Christensen, A, Hubert, N. L., Papageorge, A. G. and Lowy, D. R., The p21 ras C-terminus is required for transformation and membrane association. Nature, 310, 583-586 (1984)
DOI
ScienceOn
|
42 |
Der, C. J. and Cox, A. D., Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. Cancer Cells, 3, 331-340 (1991)
PUBMED
|
43 |
Fu, H.-W., Beese, L. S. and Casey, P. J., Kinetic analysis of zinc ligand mutants of mammalian protein famesyltransferase. Biochemistry, 37, 4465-4472 (1998)
DOI
ScienceOn
|
44 |
Gibbs, J. B., Graham, S. L., Hartman, G. D., Koblan, K. S., Kohl, N. E., Omer, C. A. and Oliff, A, Farnesyltransferase inhibitors versus Ras inhibitors. Curr. Opin. Chem. Biol., 1, 197-203 (1997).
DOI
ScienceOn
|
45 |
McCormick, F., Raf: The holy grail of Ras biology? Trends Cell Biol., 1994, 4, 347-350(1994)
DOI
PUBMED
ScienceOn
|
46 |
Grand, R. J. A and Owen D., The biochemistry of ras p21. Biochem. J., 279, 609-631(1991)
DOI
PUBMED
|
47 |
Hightower, K. E., Huang, C.-c., Casey, P. J. and Fierke, C. A., H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate, Biochemistry, 31, 15555-15562 (1998)
|
48 |
Leonard, D. M., Shuler, K. R, Poulter, C. J., Eaton, S. R, Sawyer, T. K., Hodges, J. C., Su, T-Z., Scholten, J. D., Gowan, R C., Sebolt-Leopold, J. S. and Doherty, A. M., Structure-activity relationships of cysteine-locking pentapeptide derivatives that inhibit ras farnesyltransferase. J. Med. Chem., 40, 192-200 (1997)
DOI
ScienceOn
|
49 |
Pawson, T and Schlessinger, J., SH2 and SH3 domains. J. Curro Biol. 3, 434-442 (1993)
DOI
ScienceOn
|
50 |
Hightower, K. E. and Fierke, C. A., Zinc-catalyzed sulfur alkylation: Insights from protein farnesyltransferase., Curr. Opin. Chem. Biol., 3, 176-181 (1999)
DOI
ScienceOn
|
51 |
Bolton, G. L., Sebolt-Leopold, J. S. and Hodges, J. C., In Bristol, J. A(Ed.), Annual reports in Medicinal Chemistry. vol. 29, Academic Press, New York, pp165-174, (1994)
|
52 |
Burn, C. J., Guitton, J.-D., Baudoin, B., Lelievre, Y., Duchesne,M., Parker,F., Fromage, N. and Commercon, A,Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J. Med. Chem., 40, 1763-1767 (1997)
DOI
ScienceOn
|
53 |
Heldin, C.-H. and Westermark B., Signal transduction by the receptors for platelet-derived growth factor. J. Cell Sci., 96, 193-196 (1990)
PUBMED
|